		, Ma	1222	E)			,	Complete if Known	1	•	
INCORMATION DISPARELIDE					Арр	licati	on Number	10/820,144			
		ON DIS T BY A			Filin	ıg Da	te	April 8, 2004 Esther H. Chang			
SIAI	EINIEIA	IDIA	PPLIC	MINI	Firs	t Nar	ned Inventor				
					Gro	up A	rt Unit	1632		-	
					Exa	mine	r Name				
Sheet		1	of	2	Atto	rney	Docket Number	2444-116			
			•	ι	J.S. P	ATE	NT DOCUMENTS			•	
		(	J.S. Pat	ent Docume	nt		Name of Pate	entee or Applicant		Date of Publication	
Examiner Initials*	Cite No. <sup>1</sup>	Number Kind		d Code <sup>2</sup> of Cited (known)			d Document		of Cited Document MM-DD-YYYY		
SIL	AA	5,693,5	09				Cotten et al.			Dec. 12, 1997	
	AB	5,962,311					Wickham et al.			Oct.5, 1999	
	AC	5,994,109					Woo et al.			Nov.30, 1999	
Su	FU AD 6,410,010					Zhang et al.			Jun 25, 2002		
								•			
								·			
				9							
				FOF	REIGN	I PA	TENT DOCUMEN	TS			
Examiner	Cite		oreign	Patent Docu			Name of Paton	tee or Applicant of		te of Publication of Cited Document	
Initials*	No.1	Office <sup>3</sup> Code		Number <sup>4</sup>	Kin (if kn	d <sup>s</sup> lown)	Cited I	Document		MM-DD-YYYY	٦
Gre	AE	wo	94/24:	299			Boehringer Inge	lheim Int'l GmBH	Oct	. 27, 1994	T
	AF	wo	97/38	723			Immusol Inc.		Ос	t. 23, 1997	Γ
ýl.	AG	wo	98/40	508			Barbara Sosno	owski et al.	Se	p. 17, 1998	$\Gamma$
		<u> </u>			•		· · · · · · · · · · · · · · · · · · ·	·			L
,		<u> </u>		•					<u> </u>		L
				_						-25207	L

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

Complete if Known **Application Number** 10/820,144 INFORMATION DISCLOSURE Filing Date April 8, 2004 STATEMENT BY APPLICA First Named Inventor Esther H. Chang Group Art Unit 1632 **Examiner Name** 2 of 2 Sheet Attorney Docket Number 2444-116 NON PATENT LITERATURE DOCUMENTS Examiner Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), No.1 Initials\* T<sup>2</sup> publisher, city and/or country where published CARDUCCI et al., Renal, Bladder and Prostate Cancers: Gene Therapy; Diagnossi and AH Treatment of Genitourinary Malgnancies, 1996, Kluwer Academic Publishers, Boston. COOPER, Oncogenes, by Jones and Bartlett Publishers; ISBN 0-86720-136-3, 1990 Αl ΑJ DEONARAIN, "Ligand-targeted receptor-mediated vectors for gene delivery," Expert Opinion on Therapeutics Patents, GB, Ashley Publications, 8(1):53-69, January 1998. DOUGLAS et al., "Targeted adenoviral vectors for cancer gene therapy (Review)," AK International Journal of Oncology, 11:341-348, 1997 AI. ECK et al., Goodman & Gilma's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, pp. 77-101, 1996 AM FEIGELSON et al., "Genetic Susceptibility to Cancer from xogenous and Endogenous Exposures," Journal of Cellular Biochemistry, 255:15-22 (1996) GURA, T., Science, 278:1041-1042, 1997 AN HULME, Receptor-Ligand Interactions-A Practical Approach, Oxford University Press, AO Walton Street, Oxford OX2 6DP, ISBN 0-19-963090-9 AP MICHAEL et al., "Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway," Gene Therapy 1:223-232, 1994. MILLER et al., "Targeted vectors for gene therapy," FASEB Journal, U.S. Fed. of American AQ Society for Experimental Biology, 9(2): 190-1999, February 1, 1995. AR Report and Recommendations of the Panel to Assess the NIH Investment Research on Gene Therapy, 12/7/95 STAVRIDIS et al., "Construction of Transferrin-Coated Liposomes for In Vivo Transport of AS Exogenous DNA to Bone Marrow Erythroblasts in Rabbits," given as a communication at the NATO Advanced Studies Institute Conf., Cape Sounioin Beach, Greece, June 20-July 1, 1983. AT STRYER, Biochemistry, 1995, pp. 7, 8, 33-40, 938-939 ΑU VERMA et al., Nature, 389:239-242, 1997 AV WAGNER et al., "Transferrin - polycation conjugates as carriers for DNA uptake into cells," Proc. Natl. Acad. Sci. USA 87:3410-3414, May 1990. AW XU, "Transferrin-Liposome-Mediated p53 Sensitization of Squamous Cell Carcinoma of the Head and Neck to Radiation In Vitro," Human Gene Therapy, 8:467-475, March 1, 1997. Examiner Date

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Considered

Signature

<i>.</i>		3		Complete if Known		
ia	FEB 1 8 2005			Application Number	10/820,144	
INFORMA STATEME	ION DISC	<b>Josu</b>	RE	Filing Date	April 8, 2004	
SIAIEME	ACT DE	PLICA	N I	First Named Inventor	Esther H. Chang	
				Group Art Unit	1632	
			٠.	Examiner Name		
				Confirmation No.	6653	
Sheet	1	of	4	Attorney Docket Number	2444-116	

			U.S. PA	FENT DOCUMENTS	<del></del>
Examiner	Cite No.1	U.S. Patent Do		Name of Patentee or Applicant of Cited Document	Pate of Publication of Cited Document
Initials*		Number	Kind Code (if known)		MM-DD-YYYY
	AA	5,693,509		Cotten et al.	Dec. 12, 1997
	AB	5,962,311		Wickham et al.	Oct. 5, 1999
	AC .	5,994,109		Woo et al.	Nov. 30, 1999
	AD	6,410,010	•	Zhang et al.	June 25, 2002
				1 / 10	
•		·			
				M	
· • • • • • • • • • • • • • • • • • • •		·	XV		
			7		
	•				
				·	
	7				
Examiner Signature	·	SM	hon	Date Considered	4-15201

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>4</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

•				Con	nplete if Known
				Application Number	10/820,144
	TION DISC			Filing Date	April 8, 2004
STATEME	ENT BY AP	PLICA	<b>11</b>	First Named Inventor	Esther H. Chang
				Group Art Unit	1632
				Examiner Name	
				Confirmation No.	6653
Sheet	2	of .	4	Attorney Docket Number	2444-116

			· · · · · · · · · · · · · · · · · · ·			/-	
	T		FOR	EIGN PATE	ENT DOCUMENTS		
Examiner Initials*	Cite No.1	Office <sup>3</sup> Code	Foreign Patent Docur Number <sup>4</sup>	Kind <sup>5</sup>	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
	AE .	PCT	WO 94/24299		Boehringer Ingelheim Int'l GraBH	Oct. 27, 1994	
	AF	PCT	WO 97/38723		Immusol Inc.	Oct. 23, 1997	
·	AG	PCT	WO 98/40508		Barbara Sosnowski et al.	Sep. 17, 1998	•
				ti Car			
•	*>			$\mathcal{M}_{-}$			
<b></b>	<u> </u>		TY V				
		,					
		ļ ,	/				_
		_/					_
	·	/					
	./					· ·	
·		ļ					
			ч				
Examiner Signature		4	M	h	Date Considered	4-35201)	1

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

•				Con	nplete if Known
		·	. *	Application Number	10/820,144
	TION DISCL			Filing Date	April 8, 2004
SIAIEME	NT BY APP	LICA	41	First Named Inventor	Esther H. Chang
				Group Art Unit	1632
		. •		Examiner Name	
				Confirmation No.	6653
Sheet	3	of	4	Attorney Docket Number	2444-116

Initials*   1	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	1
A		item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Т
	Ή	CARDUCCI et al., Rental, Bladder and prostate cancers: gene therapy, Diagnosis and Treatment of Genitourinay Malgnancies, 1996, Kluwer Academic Publishers. Boston.	
A	AI .	COOPER, Oncogenes, 1990 by Jones and Bartlett Publishers, ISBN 0-86720-136-3	
A	ζ.	DEONARAIN, "Ligand-targeted receptor-mediated vectors for gene delivery," Expert Opinion on Therapeutics Patents, GB, Ashley Publications, 8(1):53-69, January 1998.	
A	AK	DOUGLAS et al., "Targeted adenoviral vectors for causer gene therapy (Review)," International Journal of Oncology, 1997, pp. 341-348, vol. 11.	
A	<b>AL</b>	ECK et al., Goodman & Gilma's The Pharmacological Basis of Therapeutics, McGraww-Hill, New York, 1996, pp. 77-101	
· A	λM	FEIGELSON et al., Genetic Susceptibility to Cancer form exogenous and Endogenous Exposures; Journal of Cellular Biochemistry, 1996, pp. 15-22, vol. 255	
А	AN	GURA, T., "Systems or dentifying New Drugs Are Often Faulty," Science, November 7, 1997, pp. 1041-1042, vo. 278.	
A	40	HULME; Receptor-Ligand Interactions-A practical Approach; Oxford University Press, Walton Street, Oxford OX2 6DP, ISBN 0-19-963090-9.	
A	√P	MICHAEL et al., "Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway," Gene Therapy 1:223-232, 1994.	Ī
. A	AQ.	MILLER et al., "Targeted vectors for gene therapy," FASEB Journal, U.S. Fed. of American Society for Experimental Biology, 9(2): 190-1999, February 1, 1995.	
Α	AR :	Report and Recommendations of the Panel to Assess the NIH Investment Research on Gene Therapy. 12/7/1995.	Γ
A	as /	STAVRIDIS et al., "Construction of Transferrin-Coated Liposomes for In Vivo Transport of Exogenous DNA to Bone Marrow Erythroblasts in Rabbits," given as a communication at the NATO Advanced Studies Institute Conf., Cape Sounioin Beach, Greece, June 20-July 1, 1983.	
			_

					Соп	plete if Known			
			:		Application Number	10/820,144			
		ATION DISC			Filing Date	April 8, 2004			
51	AIEW	ENT BY AP	PLICA		First Named Inventor	Esther H. Chang			
					Group Art Unit	1632			
					Examiner Name				
					Confirmation No.	6653			
Sheet 4 of 4			4	Attorney Docket Number	2444-116				
AT STRYER, "Reversible Interaction Noncovalent Bonds," <i>Biochemist</i> Company, New York.					ns of Biomolecules are Media try, 1995, pp. 7, 8, 33-40 38-	ted by Three Kinds of 939. W.H. Freeman and			
	AU	VERMA et a 1997, pp. 23	I., "Gene 9-242, vo	therapypol. 389.	romises problems and prospi	ects," Nature, September 18,			
	AV	WAGNER e Proc. Natl. A	t al., "Tra cad. Sci.	nsferiin - p USA 87:34	olycation conjugates as carrie	ers for DNA uptake into cells,"			
	AW	XU, "Transfe Head and N	XU, "Transferrin-Liposome-Mediated p53 Sensitization of Squamous Cell Carcinoma of the Head and Neck to Radiation <i>In Vitro</i> ," Human Gene Therapy, 8:467-475, March 1, 1997.						
	/								
						·			
-									
•						,			
	<u> </u>								

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Unique citation designation number. \*Applicant is to place a check mark here if English language Translation is attached.